---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-026908"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T09:02:43.093702+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NRx Pharma narrows Q2 net loss to $7.9M; secures $10.8–16.3M convertible debt for NDAs

## Summary
- Q2 net loss $7.9M vs $8.7M YoY; six-month net loss $14.4M vs $19.8M.
- Secured $10.8–16.3M convertible debt from Anson Funds; retired Streeterville debt at litigation discount.
- Plans to file NDAs for NRX-100 (IV ketamine) and NRX-101 for bipolar depression in Q4 2024.
- HOPE Therapeutics audit complete; spinout SEC filing planned this quarter.
- Cash $1.9M at June 30; new funding expected to support filings and operations.

## SEC filing metadata
- accession: 0001437749-24-026908
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774924026908/0001437749-24-026908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774924026908/nrxp20240814d_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-026908
- JSON: https://secwatch.observer/filing/0001437749-24-026908.json
- Plain text: https://secwatch.observer/filing/0001437749-24-026908.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.